Dosar de subiect
Gilead Acquires Cancer Biotech Tubulis for $5 Billion
Primul articol: 8 apr. 2026, 22:41
|
Ultima actualizare: 8 apr. 2026, 22:41
|
1 sursa
|
1 articol
Mai multe surse. Mai putina manipulare.
Analiza editoriala
Bazat pe 1 sursa, 1 articol
Gilead's acquisition of Tubulis represents a significant investment in the field of cancer research and treatment. Tubulis' innovative technologies and promising drug candidates will complement Gilead's existing oncology portfolio, potentially leading to breakthroughs in cancer therapies. The deal underscores the ongoing consolidation and competition within the biotechnology industry as companies seek to develop new and effective treatments for cancer.Articole despre acest subiect
Foto: Bloomberg
Gilead to Buy Cancer Biotech Tubulis in $5B Deal
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Gilead agreed to buy private German biotech Tubulis in a deal worth up to $5 billion as it looks to boost its portfolio in a hot new area of cancer drug development. (Source: Bloomberg)
Citeste pe Bloomberg →